Classes terapêuticas que induzem a esse evento adverso
Inibidor de KIT, Inibidor de MEK
CTCAE V5.0
Suave.
CLASSIFICAÇÃO SIMPLIFICADA
Assintomático.
Edema mole.
REFERÊNCIAS
Peuvrel L, Cassecuel J, Bernier C, Quéreux G, Saint-Jean M, Le Moigne M, Frénard C, Khammari A, Dréno B; Supported by GESTIM Nantes group of cutaneous adverse events induced by cancer treatments. TOXICAN: A guide for grading dermatological adverse events of cancer treatments. Support Care Cancer. 2018;26:2871-7.
CTCAE V5.0
Edema endurecido; intervenção tópica indicada.
CLASSIFICAÇÃO SIMPLIFICADA
Edema endurecido.
REFERÊNCIAS
Peuvrel L, Cassecuel J, Bernier C, Quéreux G, Saint-Jean M, Le Moigne M, Frénard C, Khammari A, Dréno B; Supported by GESTIM Nantes group of cutaneous adverse events induced by cancer treatments. TOXICAN: A guide for grading dermatological adverse events of cancer treatments. Support Care Cancer. 2018;26:2871-7.
CTCAE V5.0
Edema associado com distúrbio visual; aumento da pressão intraocular, glaucoma ou hemorragia retiniana; neurite óptica; diuréticos indicados; intervenção cirúrgica indicada.
CLASSIFICAÇÃO SIMPLIFICADA
Afeta o olho.
REFERÊNCIAS
Peuvrel L, Cassecuel J, Bernier C, Quéreux G, Saint-Jean M, Le Moigne M, Frénard C, Khammari A, Dréno B; Supported by GESTIM Nantes group of cutaneous adverse events induced by cancer treatments. TOXICAN: A guide for grading dermatological adverse events of cancer treatments. Support Care Cancer. 2018;26:2871-7.
Consulte mais efeitos colaterais